MedPath

The effect of Eugenia Caryophillat,s product on depressio

Phase 3
Conditions
Condition 1: Major depressive disorder, single episode, moderate. Condition 2: Major depressive disorder, single episode, mild.
Major depressive disorder, single episode, moderate
Major depressive disorder, single episode, mild
F32.1
F32.0
Registration Number
IRCT20190309042979N1
Lead Sponsor
Mazandaran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

1-Declaration of written consent of the candidate for participation
18-65 years old
Detection of major depressive disorder based on DSM-5 and treated for more than 6 weeks
Score 14 to 28 in the depression test 21 BDI-II questions

Exclusion Criteria

symptoms of high mood
suicide incidence
The incidence of unknown side effect
patient request
pregnancy and lactation

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression Score. Timepoint: Before the start of the intervention (week 0) and 14, 28 and 42 days after the start of the intervention. Method of measurement: Beck questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath